Clinical Neuropharmacology最新文献

Late-Onset Bipolar Disorder: A Case Report. 迟发性双相情感障碍1例报告。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-04-14 DOI: 10.1097/WNF.0000000000000684

Sonali Shirali, Rose Dever

引用次数: 0

Venlafaxine Is of Variable Effectiveness in Severe Major Depression, Depending on Patient Treatment Response Expectation. 文拉法辛对重度抑郁症的疗效不同，取决于患者的治疗反应预期。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-04-02 DOI: 10.1097/WNF.0000000000000681

Udo Bonnet

{"title":"Venlafaxine Is of Variable Effectiveness in Severe Major Depression, Depending on Patient Treatment Response Expectation.","authors":"Udo Bonnet","doi":"10.1097/WNF.0000000000000681","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000681","url":null,"abstract":"Objective: The importance of contextual factors, such as the patient treatment response expectation for the effectiveness of antidepressants (AD), in the treatment of major depressive disorder (MDD) is still underestimated.Methods: This is a report on the surprising course of treatment of a 47-year-old woman suffering from severe melancholic MDD with pronounced somatic symptoms.Results: The first attempt at treatment with venlafaxine (300 mg/d) failed. During this treatment, the patient was not yet convinced of the effectiveness of an AD for her illness. She did not believe that she had MDD at all. In a second pharmacological treatment period, venlafaxine (150 mg/d) worked excellently. In a special psychoeducative run-up to this second treatment, the patient was able to gain a deeper understanding that she was indeed suffering from MDD. Now she could consider the possibility that AD might be helpful against her severe complaints (\"experienced insight\").Conclusion: The role of treatment response expectation should be given greater consideration in the event of nonresponse to medication.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. 单剂量裸盖菇素治疗边缘型人格障碍伴重性抑郁症的开放标签研究。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-04-01 DOI: 10.1097/WNF.0000000000000683

Jon E Grant, Sophia Boutouis, Margaret O'Brien, Laurie Avila, Megha Neelapu, Dustin Ehsan

{"title":"An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder.","authors":"Jon E Grant, Sophia Boutouis, Margaret O'Brien, Laurie Avila, Megha Neelapu, Dustin Ehsan","doi":"10.1097/WNF.0000000000000683","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000683","url":null,"abstract":"Objectives: Borderline personality disorder (BPD) is often comorbid with major depressive disorder (MDD), and there has been a suggestion in the literature that this comorbidity may interfere with MDD treatment response. Our objective was to conduct a pilot study of psilocybin in adults with BPD and MDD.Methods: Adults aged 18 to 65 years with a DSM-5 diagnosis of MDD and BPD were enrolled in an open-label pilot study of a single dose of psilocybin. Assessments were conducted 1 week before dosing (baseline), on the dosing day (visit 2), and at 1, 2, and 4 weeks postdosing. The co-primary outcome measures were changes in depressive and BPD symptoms from baseline to study endpoint, and we used a paired-samples t test to examine changes in symptoms.Results: Nine participants (4 males; mean age=31.3 y) with MDD and BPD were enrolled. MDD symptoms significantly changed from baseline to visit 5: baseline (M=28.56, SD=4.53) and final visit (M=17.22, SD=10.39); t(8)=-4.217, P=0.003; Cohen d=1.41. BPD scores did not significantly change from baseline to study endpoint.Conclusions: This small open-label study resulted in statistically significant improvement in MDD symptoms but not for BPD symptoms. These findings, which await larger clinical trials, suggest that BPD does not appear to interfere with response to depressive symptoms.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PCSK9 Inhibitors and Bipolar Disorder: A Drug Target Mendelian Randomization Study. PCSK9抑制剂和双相情感障碍：一项药物靶向孟德尔随机化研究。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-19 DOI: 10.1097/WNF.0000000000000677

Jin Li, Pei-Sen Yao

{"title":"PCSK9 Inhibitors and Bipolar Disorder: A Drug Target Mendelian Randomization Study.","authors":"Jin Li, Pei-Sen Yao","doi":"10.1097/WNF.0000000000000677","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000677","url":null,"abstract":"Objective: Bipolar disorder (BD) patients remain symptomatic. As lipid-lowering drug targets have been linked to BD risk, we used Mendelian randomization (MR) to assess their therapeutic potential.Methods: We conducted MR analyses utilizing genetic variants associated with lipid traits and variants in genes encoding the protein targets of various classes of lipid-lowering drugs. The specific drug classes investigated included 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), proprotein convertase subtilisin/kexin type 9 (PCSK9), and Niemann-Pick C1-Like 1 (NPC1L1). To determine the effects on BD risk, we meta-analyzed MR estimates for regional variants using data from 2 large sample sets. The genetic variants were weighted based on their associations with low-density LDL-c. For lipid-modifying drug targets that exhibited suggestive significance, we further used eQTL data. In addition, we performed colocalization analysis to assess genetic confounding.Results: Genetically proxied inhibition of PCSK9 was strongly associated with a lower risk of developing BD (IVW MR OR=0.82, 95% CI=0.74-0.91, P=2.12e-04, SD reduction in LDL-c) in PGC data set, and in UK Biobank data set (P=0.03). Sensitivity analyses yielded no statistically significant evidence of bias arising from pleiotropy or genetic confounding. The posterior probability for a common causal variant between PCSK9 inhibition and BD risk was 80.8%.Conclusions: It was observed that PCSK9 showed significant associations with BD risk. These findings indicate that PCSK9 inhibitors have the potential to serve for the treatment of BD.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed-Onset Cariprazine-Induced Akathisia: A Case Report. 迟发性卡吡嗪致静坐症1例报告。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-02 DOI: 10.1097/WNF.0000000000000676

Zachary Goodrich, Drew Grehan

{"title":"Delayed-Onset Cariprazine-Induced Akathisia: A Case Report.","authors":"Zachary Goodrich, Drew Grehan","doi":"10.1097/WNF.0000000000000676","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000676","url":null,"abstract":"Objective: This case report describes the clinically underrecognized manifestation of delayed-onset akathisia induced by cariprazine occurring 10 weeks after treatment initiation. The secondary objective was to discuss potential pharmacokinetic and pharmacodynamic mechanisms of the drug-induced side effects.Methods: A retrospective review of the patient's medical and psychiatric history was performed in addition to a comprehensive literature review.Results: A 42-year-old female with bipolar disorder and generalized anxiety disorder presented to the emergency department on 3 separate occasions with severe restlessness and insomnia, commonly attributed to her previous history of anxiety. Although initial treatment with lorazepam provided subjective symptom relief, the underlying cause persisted. Psychiatry consultation led to a diagnosis of antipsychotic-induced akathisia and administration of diphenhydramine resulted in rapid improvement. The offending agent, cariprazine, was discontinued, resulting in sustained symptom resolution.Conclusions: This case highlights the challenge of distinguishing akathisia from primary anxiety disorders, in addition to considering this diagnosis beyond the initial treatment period. Akathisia symptoms most commonly present within 4 weeks of initiation or titration of antidopaminergic treatment. However, this timeline may be delayed with cariprazine due to its pharmacokinetic and pharmacodynamic properties.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antisuicidal Effect of Lamotrigine Augmentation in Treatment-Resistant Depression: A Case Report. 增加拉莫三嗪治疗难治性抑郁症的抗自杀效果1例报告。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1097/WNF.0000000000000668

Kimberly Hsiung, Terako Amison

{"title":"Antisuicidal Effect of Lamotrigine Augmentation in Treatment-Resistant Depression: A Case Report.","authors":"Kimberly Hsiung, Terako Amison","doi":"10.1097/WNF.0000000000000668","DOIUrl":"10.1097/WNF.0000000000000668","url":null,"abstract":"Objectives: Treatment-resistant depression (TRD) is a serious public health burden in the United States and comes with an extremely high suicide risk relative to the general population. Lamotrigine, though approved for use only in bipolar disorder, has been found to augment the effects of an antidepressant in treatment-resistant individuals. However, studies showing an antisuicidal effect of lamotrigine in the TRD population are limited. The objective of this paper is to describe a case of a 58-year-old male with TRD and chronic suicidality who was treated with lamotrigine augmentation of the serotonin-norepinephrine reuptake inhibitor, duloxetine, and experienced a sustained clinical improvement of his suicidality.Methods: Clinical changes in depression and suicidality after initiation of lamotrigine are presented.Results: The patient experienced a brief improvement in depression and sustained improvement in suicidality for 2 years.Conclusions: While there remains insufficient evidence in the literature for a clinical recommendation of the use of lamotrigine for suicidality in the TRD population, our case report introduces the novel possibility of an antisuicidal effect of lamotrigine at the individual level. We suggest clinicians consider its use when other, more robust treatments for suicidality have failed.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"49 2","pages":"87-90"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12975012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Principal Component of the Inflammatory Biomarkers is the Best Predictor of Neuropsychiatric Disorders in Long COVID Patients. 炎症生物标志物的主成分是长COVID患者神经精神疾病的最佳预测因子。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-01 Epub Date: 2026-02-02 DOI: 10.1097/WNF.0000000000000671

Hawraa Kadhem Al-Jassas, Hussein Kadhem Al-Hakeim

{"title":"The Principal Component of the Inflammatory Biomarkers is the Best Predictor of Neuropsychiatric Disorders in Long COVID Patients.","authors":"Hawraa Kadhem Al-Jassas, Hussein Kadhem Al-Hakeim","doi":"10.1097/WNF.0000000000000671","DOIUrl":"10.1097/WNF.0000000000000671","url":null,"abstract":"Objectives: Long COVID (LC) is associated with neuropsychiatric disorders (anxiety, depression, and fatigue), an insulin resistance (IR) state, and inflammatory biomarkers. In the present study, IR and inflammatory biomarkers were used to predict the scores of neuropsychiatric disorders.Methods: The ELISA method was used for measurements of IL-1β, IL-10, IL-18, C-reactive protein (CRP), and insulin in the sera of LC and control subjects. Glucose levels were measured spectrophotometrically. The Hamilton scale for anxiety (HAMA) and depression (HAMD), and the fibro fatigue scale (FFtotal) were used for scoring the neuropsychiatric symptoms. The homeostatic model assessment 2 (HOMA2) calculator was used for computing IR (HOMA2IR), insulin sensitivity (HOMA%S), and pancreatic β-cell function (HOMA%B).Results: LC is associated with neuropsychiatric diseases (FFtotal, HAMAtotal, and HAMDtotal), insulin resistance biomarkers, and inflammatory biomarkers. These biomarkers are correlated with each other in LC patients. The building of principal components for inflammatory biomarkers (PC_Inflam) and insulin resistance (PC_IR) creates vectors that could surpass individual biomarkers in neuropsychiatric issue prediction in liver cirrhosis patients. Out of the biomarkers investigated, PC_Inflam is the most important predictor for FFtotal (sensitivity and specificity of 71.4%), HAMAtotal (sensitivity and specificity of 70%), and HAMDtotal (sensitivity of 71.2% and specificity of 71.5%).Conclusions: Neuropsychiatric disorders can be predicted by the principal component built from inflammatory biomarkers (IL-1β, IL-10, IL-18, and CRP). In contrast, PC_IR has a lower predictive value for the neuropsychiatric disorders compared with PC_Inflam. These results indicated the significant role of inflammation in the main symptoms of LC.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"72-80"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors for Symptom Aggravation in Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion. 前循环大血管闭塞导致急性缺血性卒中症状加重的危险因素。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-01 Epub Date: 2026-02-09 DOI: 10.1097/WNF.0000000000000672

Shugai Liu, Tianqiang Pu, Qiang Ran, Lei Tao

{"title":"Risk Factors for Symptom Aggravation in Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion.","authors":"Shugai Liu, Tianqiang Pu, Qiang Ran, Lei Tao","doi":"10.1097/WNF.0000000000000672","DOIUrl":"10.1097/WNF.0000000000000672","url":null,"abstract":"Objective: This study is designed to expound the risk factors for symptomatic exacerbation of acute ischemic stroke due to anterior circulation large vessel occlusion (AIS-AC-LVO), aiming to inform strategies for preventing disease progression.Methods: Two hundred patients with AIS-AC-LVO were retrospectively analyzed. Baseline data included demographics, vascular risk factors, stroke subtype, admission NIHSS score, core infarct volume, blood pressure, serum lipid profile, homocysteine (Hcy), and neutrophil count. Perioperative variables comprised onset-to-door time (ODT), door-to-procedure time (DPT), intravenous thrombolysis, bridging therapy, occlusion site, anesthesia type, procedure duration, intraoperative rescue interventions, recanalization status, and postoperative sedative use. Patients were classified into exacerbated or nonexacerbated groups according to 7-day neurological outcomes. Univariate analysis, multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis were conducted.Results: Baseline NIHSS score, LDL-C, Hcy, neutrophil count, ODT, procedure duration, core infarct volume, and recanalization rate differed significantly between groups ( P <0.05). Multivariate analysis identified elevated Hcy (OR=2.109, 95% CI: 1.499-2.965), prolonged ODT (OR=1.574, 95% CI: 1.181-2.098), longer procedure duration (OR=1.049, 95% CI: 1.014-1.085), and higher LDL-C (OR=5.398, 95% CI: 1.385-21.036) as independent predictors of symptom worsening. ROC analysis showed strong predictive performance for Hcy (AUC=0.866) and ODT (AUC=0.769) (both P <0.001).Conclusions: Elevated Hcy, elevated LDL-C, and prolonged ODT and procedure duration independently predict short-term neurological deterioration.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"81-86"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amitriptyline for Refractory Idiopathic Intractable Hiccups: A Case Report. 阿米替林治疗难治性特发性顽固性呃逆1例报告。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-01 Epub Date: 2025-12-02 DOI: 10.1097/WNF.0000000000000665

Danial Chowdhury, Caitlin McCarthy, M Thomas Bateman

{"title":"Amitriptyline for Refractory Idiopathic Intractable Hiccups: A Case Report.","authors":"Danial Chowdhury, Caitlin McCarthy, M Thomas Bateman","doi":"10.1097/WNF.0000000000000665","DOIUrl":"10.1097/WNF.0000000000000665","url":null,"abstract":"Objective: Intractable hiccups, which are hiccups that can last longer than 1 month, may be very debilitating for patients. With limited evidence and a lack of treatment guidelines, refractory hiccups can be difficult to manage. We aim to present a case of refractory idiopathic intractable hiccups treated with amitriptyline in conjunction with other medications shown to produce hiccups relief.Materials and methods: The patient's electronic health record, direct patient care experiences, and a systematic literature review were used for this case report. We report a 53-year-old male patient with refractory idiopathic intractable hiccups. Treatment was improved with the addition of amitriptyline to his regimen of medications used for hiccups management. Medline and PubMed were searched using the key terms \"hiccup\" or \"singultus\" and \"amitriptyline.\"Results: The literature search yielded 3 unique articles, which resulted in 4 unique cases with intractable hiccups responding to amitriptyline therapy. In all cases, patients tried multiple medications before amitriptyline initiation.Conclusions: This is the first case in over 30 years providing additional evidence for amitriptyline use in the relief of intractable hiccups. Amitriptyline may be more useful in patients experiencing intractable hiccups with comorbid mood disorders and in cases of suspected psychogenic origin.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"95-99"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive Function and Treatment Outcomes in Trichotillomania: A Case Series Evaluating the Efficacy of TMS. 拔毛狂的认知功能和治疗结果：一个评估经颅磁刺激疗效的病例系列。

IF 1.5 4区医学

Clinical Neuropharmacology Pub Date : 2026-03-01 Epub Date: 2025-12-12 DOI: 10.1097/WNF.0000000000000666

Beyazit Garip, Dilara Yüzgüleç

{"title":"Cognitive Function and Treatment Outcomes in Trichotillomania: A Case Series Evaluating the Efficacy of TMS.","authors":"Beyazit Garip, Dilara Yüzgüleç","doi":"10.1097/WNF.0000000000000666","DOIUrl":"10.1097/WNF.0000000000000666","url":null,"abstract":"Objectives: Trichotillomania is a psychiatric disorder characterized by the compulsive pulling of one's own hair, eyelashes, or eyebrows. Depression and obsessive-compulsive disorder comorbidity is frequently observed in patients with trichotillomania. In this case series, we will report how a patient diagnosed with trichotillomania was successfully treated with transcranial magnetic stimulation (TMS) therapy in our clinic.Methods: The TMS protocol was delivered using the MagVenture X100 device, with treatment intensity calibrated to 100% of each participant's motor threshold. Following the established treatment protocol for trichotillomania, patients received repetitive TMS at 1 Hz, with each train lasting 300 seconds and a 60-second intertrain interval, for a total of 1200 pulses per session. The bilateral supplementary motor area (SMA) was targeted as the site of stimulation.Results: The efficacy of TMS in reducing hair-pulling behaviors in patients with trichotillomania was evaluated in a case series of 3 patients who underwent 20 TMS sessions. The findings demonstrated a significant reduction in hair-pulling behaviors post-treatment. According to the Massachusetts General Hospital Hair Pulling Scale (MGH-HP), over 50% improvement was observed in all patients.Conclusions: The findings suggest that TMS may serve as a promising intervention for trichotillomania, warranting further exploration in larger, controlled trials. The utilization of the MGH-HP scale provided a robust measure for assessing behavioral changes, highlighting the potential of TMS in managing compulsive disorders.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"91-94"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0